Blue Jet Healthcare files draft papers with Sebi for Rs 2,100-cr IPO

Mumbai-based Blue Jet Healthcare, is a specialty pharmaceutical and healthcare ingredient and intermediate company

IPO
Photo: Shutterstock
Press Trust of India New Delhi
2 min read Last Updated : Sep 05 2022 | 3:49 PM IST
Pharmaceutical ingredients maker Blue Jet Healthcare has filed preliminary papers with capital markets regulator Sebi to raise as much as Rs 2,100 crore through an initial public offering (IPO).
 
The IPO is completely an offer-for-sale (OFS) through which the company's promoters -- Akshay Bansarilal Arora and Shiven Akshay Arora -- will sell up to 21,683,178 equity shares, according to the draft red herring prospectus (DRHP).

Merchant banking sources have pegged the IPO size between Rs 1,800 crore and Rs 2,100 crore.

The Mumbai-based Blue Jet Healthcare, is a specialty pharmaceutical and healthcare ingredient and intermediate company, offering niche products targeted towards innovator pharmaceutical companies and multinational generic pharmaceutical companies.

Its business model focuses on collaboration, development, and manufacturing of complex chemistry categories. Over the past five decades, the company has developed over 100 products with over 40 products commercialised.

The company's 76 per cent of income in FY22 came from Europe, followed by India (17.14 per cent), the US (4.18 per cent) and some other countries.

Its revenue from operations grew by 37 per cent to Rs 683.47 crore for the financial year 2022, from Rs 498.93 crore for the financial year 2021.

The company's profit after tax rose by 34 per cent to Rs 181.59 crore for the financial year 2022, from Rs 135.79 crore for the same period last year.

The company is a net debt-free company as on June 30, 2022 and it operates three manufacturing facilities, in Shahad, Ambernath, and Mahad in Maharashtra as of March-end this year.

Kotak Mahindra Capital Company Limited, ICICI Securities Limited, and J.P. Morgan India Private Limited are the books running lead managers to the issue. The equity shares are proposed to be listed on BSE and NSE.

One subscription. Two world-class reads.

Already subscribed? Log in

Subscribe to read the full story →
Subscribe to Business Standard digital and get complimentary access to The New York Times

Quarterly Starter

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

Save 46%

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Access to Exclusive Premium Stories Online

  • Over 30 behind the paywall stories daily, handpicked by our editors for subscribers

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

Topics :SEBIipo filinginitial public offerings IPOs

Next Story